These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

575 related articles for article (PubMed ID: 31128197)

  • 21. Lipid nanoparticles of zaleplon for improved oral delivery by Box-Behnken design: optimization, in vitro and in vivo evaluation.
    Dudhipala N; Janga KY
    Drug Dev Ind Pharm; 2017 Jul; 43(7):1205-1214. PubMed ID: 28274147
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Optimization of carvedilol solid lipid nanoparticles: An approach to control the release and enhance the oral bioavailability on rabbits.
    El-Say KM; Hosny KM
    PLoS One; 2018; 13(8):e0203405. PubMed ID: 30161251
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel carvedilol paediatric nanomicelle formulation: in-vitro characterization and in-vivo evaluation.
    Wegmann M; Parola L; Bertera FM; Taira CA; Cagel M; Buontempo F; Bernabeu E; Höcht C; Chiappetta DA; Moretton MA
    J Pharm Pharmacol; 2017 May; 69(5):544-553. PubMed ID: 27431770
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Design and evaluation of novel pH-sensitive chitosan nanoparticles for oral insulin delivery.
    Makhlof A; Tozuka Y; Takeuchi H
    Eur J Pharm Sci; 2011 Apr; 42(5):445-51. PubMed ID: 21182939
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Thiolated chitosan nanoparticles for the nasal administration of leuprolide: bioavailability and pharmacokinetic characterization.
    Shahnaz G; Vetter A; Barthelmes J; Rahmat D; Laffleur F; Iqbal J; Perera G; Schlocker W; Dünnhaput S; Augustijns P; Bernkop-Schnürch A
    Int J Pharm; 2012 May; 428(1-2):164-70. PubMed ID: 22421322
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Carvedilol nano lipid carriers: formulation, characterization and in-vivo evaluation.
    Mishra A; Imam SS; Aqil M; Ahad A; Sultana Y; Ameeduzzafar ; Ali A
    Drug Deliv; 2016 May; 23(4):1486-94. PubMed ID: 26978072
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development and optimization of in-situ gel containing chitosan nanoparticles for possible nose-to-brain delivery of vinpocetine.
    Hard SAAA; Shivakumar HN; Redhwan MAM
    Int J Biol Macromol; 2023 Dec; 253(Pt 6):127217. PubMed ID: 37793522
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Design of ultra-fine carvedilol nanococrystals: Development of a safe and stable injectable formulation.
    Mohammady M; Hadidi M; Iman Ghetmiri S; Yousefi G
    Eur J Pharm Biopharm; 2021 Nov; 168():139-151. PubMed ID: 34481906
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Quality by design approach to understand the process of optimization of iloperidone nanostructured lipid carriers for oral bioavailability enhancement.
    Mandpe L; Pokharkar V
    Pharm Dev Technol; 2015 May; 20(3):320-9. PubMed ID: 24328553
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel chitosan-functionalized spherical nanosilica matrix as an oral sustained drug delivery system for poorly water-soluble drug carvedilol.
    Sun L; Wang Y; Jiang T; Zheng X; Zhang J; Sun J; Sun C; Wang S
    ACS Appl Mater Interfaces; 2013 Jan; 5(1):103-13. PubMed ID: 23237208
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mucopenetrating nanoparticles for enhancement of oral bioavailability of furosemide: In vitro and in vivo evaluation/sub-acute toxicity study.
    Radwan SE; Sokar MS; Abdelmonsif DA; El-Kamel AH
    Int J Pharm; 2017 Jun; 526(1-2):366-379. PubMed ID: 28487189
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Optimized mucoadhesive niosomal carriers for intranasal delivery of carvedilol: A quality by design approach.
    Azrak ZAT; Taha MS; Jagal J; Elsherbeny A; Bayraktutan H; AbouGhaly MHH; Elshafeey AH; Greish K; Haider M
    Int J Pharm; 2024 Apr; 654():123935. PubMed ID: 38395319
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Design, formulation and optimization of novel soft nano-carriers for transdermal olmesartan medoxomil delivery: In vitro characterization and in vivo pharmacokinetic assessment.
    Kamran M; Ahad A; Aqil M; Imam SS; Sultana Y; Ali A
    Int J Pharm; 2016 May; 505(1-2):147-58. PubMed ID: 27005906
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development, Optimization, and Evaluation of Carvedilol-Loaded Solid Lipid Nanoparticles for Intranasal Drug Delivery.
    Aboud HM; El Komy MH; Ali AA; El Menshawe SF; Abd Elbary A
    AAPS PharmSciTech; 2016 Dec; 17(6):1353-1365. PubMed ID: 26743643
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Transdermal delivery of propranolol hydrochloride through chitosan nanoparticles dispersed in mucoadhesive gel.
    Al-Kassas R; Wen J; Cheng AE; Kim AM; Liu SSM; Yu J
    Carbohydr Polym; 2016 Nov; 153():176-186. PubMed ID: 27561485
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Positively Charged Nanostructured Lipid Carriers and Their Effect on the Dissolution of Poorly Soluble Drugs.
    Choi KO; Choe J; Suh S; Ko S
    Molecules; 2016 May; 21(5):. PubMed ID: 27213324
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sunitinib loaded chitosan nanoparticles formulation and its evaluation.
    Joseph JJ; Sangeetha D; Gomathi T
    Int J Biol Macromol; 2016 Jan; 82():952-8. PubMed ID: 26522243
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Response Surface Methodology for Statistical Optimization of Chitosan/Alginate Nanoparticles as a Vehicle for Recombinant Human Bone Morphogenetic Protein-2 Delivery.
    Zohri M; Akbari Javar H; Gazori T; Khoshayand MR; Aghaee-Bakhtiari SH; Ghahremani MH
    Int J Nanomedicine; 2020; 15():8345-8356. PubMed ID: 33154637
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Optimized nanoemulsifying systems with enhanced bioavailability of carvedilol.
    Singh B; Singh R; Bandyopadhyay S; Kapil R; Garg B
    Colloids Surf B Biointerfaces; 2013 Jan; 101():465-74. PubMed ID: 23010056
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chitosan-based nano-in-microparticle carriers for enhanced oral delivery and anticancer activity of propolis.
    Elbaz NM; Khalil IA; Abd-Rabou AA; El-Sherbiny IM
    Int J Biol Macromol; 2016 Nov; 92():254-269. PubMed ID: 27397719
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.